LabConnect enhances global reach with acquisition of A4P Consulting
LabConnect, a prominent provider of Central Laboratory Services and Functional Service Provider (FSP) Solutions, has announced a significant expansion of its capabilities through the acquisition of A4P Consulting Ltd (A4P), a UK-based scientific consultancy specializing in bioanalytical and biosample project management, biomarker strategy, and logistics solutions. This acquisition marks a strategic enhancement of LabConnect’s service offerings, particularly in supporting pre-clinical and clinical trials globally.
A4P, headquartered in Discovery Park, Sandwich, Kent, UK, with a subsidiary in Appenzell, Switzerland, brings to LabConnect a wealth of expertise in regulated bioanalysis, genomics, biomarker strategy, personalized healthcare, biosample operations, and bespoke logistics solutions. Founded over a decade ago by four pharmaceutical industry veterans, A4P has established itself as a pivotal player in the scientific consultancy arena, servicing a diverse client base across various therapeutic areas.
The integration of A4P’s expertise and services into LabConnect’s offerings is expected to provide unprecedented access to cutting-edge scientific solutions for pre-clinical and clinical research, enhancing the geographical reach and operational capabilities of LabConnect. Ian James, PhD., Co-Founder and Chief Executive Officer of A4P, expressed enthusiasm about the merger: “Bringing together our unique company model with LabConnect unlocks exciting opportunities to broaden the geographies we operate in and enhance our service offerings for our customers.”
LabConnect is known for partnering with pharmaceutical and biotechnology companies, contract research organizations (CROs), and foundations/non-governmental organizations (NGOs) to deliver innovative scientific solutions that accelerate the development of new medicines. With this acquisition, LabConnect not only solidifies its industry-leading position but also furthers its mission to create healthier communities and improve patient lives. Dawn Sherman, Chief Executive Officer of LabConnect, stated, “By joining forces with A4P, we further our mission to create healthier communities and improve patient lives by accelerating the development of medicines.”
The transaction was supported by advisors from both sides, with LabConnect being advised by BroadOak Capital Partners and DLA Piper, and A4P by Achelous Partners, Bishop and Sewell, Kreston Reeves, and Higson & Co. As the pharmaceutical and biotechnology landscape continues to evolve, the combined expertise of LabConnect and A4P is poised to meet the increasingly complex demands of clinical trials and drug development processes.